Pulmonologists share best practices on when primary care providers should consider sending patients with respiratory ...

In the US in October 2024, the FDA approved Abrysvo for the prevention of lower respiratory tract disease caused by RSV in individuals 18 through 59 years of age who are at increased risk for LRTD ...